Journal
NATURE MEDICINE
Volume 19, Issue 1, Pages 74-82Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nm.3040
Keywords
-
Funding
- US National Institutes of Health [HL095654, HL113005, HL101284, HL069170, HL093362]
- Howard Hughes Medical Institute (Physician Scientist Early Career Award)
- American Heart Association [12GRNT9410029]
- Pfizer ASPIRE Young Investigator Research Award
- NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000439] Funding Source: NIH RePORTER
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL093362, K08HL095654, R01HL113005, P30HL101284, R01HL069170, R37HL060917] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Pulmonary arterial hypertension (PAH) is characterized by vascular remodeling associated with obliteration of pulmonary arterioles and formation of plexiform lesions composed of hyperproliferative endothelial and vascular smooth-muscle cells. Here we describe a microRNA (miRNA)-dependent association between apelin (APLN) and fibroblast growth factor 2 (FGF2) signaling in pulmonary artery endothelial cells (PAECs). APLN deficiency in these cells led to increased expression of FGF2 and its receptor FGFR1 as a consequence of decreased expression of miR-424 and miR-503, which directly target FGF2 and FGFR1. miR-424 and miR-503 were downregulated in PAH, exerted antiproliferative effects in PAECs and inhibited the capacity of PAEC-conditioned medium to induce the proliferation of pulmonary artery smooth-muscle cells. Reconstitution of miR-424 and miR-503 in vivo ameliorated pulmonary hypertension in experimental models. These studies identify an APLN-dependent miRNA-FGF signaling axis needed for the maintenance of pulmonary vascular homeostasis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available